GH Research PLC (GHRS) Research

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

Market snapshot

Symbol
GHRS
Price
$22.24
Day change
+2.49%
Market cap
$1.5B
P/E ratio
-24.46x
52-week range
11.32-25.94
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$40.57

Recent news

  • These Analysts Revise Their Forecasts On GH Research After Q1 Results

    GH Research PLC (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday.

  • FTSE 100 Live: London stocks slide as aerospace and defence sector falls

    FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,...

  • Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?

    Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump to speed up psychedelic drug reviews

Peer companies

  • Arbutus Biopharma Corporation (ABUS)
  • Kura Oncology, Inc. (KURA)
  • LENZ Therapeutics, Inc. (LENZ)
  • Nanobiotix S.A. (NBTX)
  • ProKidney Corp. (PROK)
  • Palvella Therapeutics, Inc. (PVLA)
  • Rezolute, Inc. (RZLT)
  • ARS Pharmaceuticals, Inc. (SPRY)

Recent insider activity

  • Moore Duncan — trade (0 shares) on 2026-03-18
  • Moore Duncan — trade (4667 shares) on 2026-03-18
  • Cameron Aaron Luke — trade (33211 shares) on 2026-03-18
  • Cameron Aaron Luke — trade (100000 shares) on 2026-03-18
  • Cameron Aaron Luke — trade (25000 shares) on 2026-03-18

Open GH Research PLC (GHRS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.